Roche has agreed to acquire oncology research platform Flatiron in a deal that valued it at $2.15bn, giving GV what would be its fifth latest life sciences exit since the start of November.
US-based oncology research technology provider Flatiron Health is set to become the latest of GV’s life sciences-focused portfolio companies to net it an exit, after agreeing to a $1.9bn acquisition by pharmaceutical firm Roche last week.
Flatiron has developed an oncology research software platform that stores data from electronic health records. It works with more than 265 community cancer clinics and there are more than 2 million active patient records available for access by its users.
The company had…
